ZTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zoetis Inc (ZTS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, positive hedge fund activity, and favorable analyst sentiment outweigh the lack of short-term proprietary trading signals and minor technical weaknesses. The long-term growth potential in the animal health sector, driven by the 'humanization' of pets, makes this a solid investment opportunity.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 33.519, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 116.083), which could provide a potential entry point. However, the stock is slightly bearish in the pre-market, down -0.65%.
Hedge funds are significantly increasing their positions in Zoetis, with a 228.26% increase in buying activity over the last quarter.
Citi initiated a Buy rating with a $145 price target and highlighted the potential for growth in fiscal 2026 due to Solensia.
The animal health sector is expected to benefit from the 'humanization' of pets, driving long-term growth.
The MACD indicates bearish momentum, and the stock is trading near its support level, which could lead to further downside if breached.
Insider trading activity is neutral, with no significant trends.
No recent news or Congress trading data to provide additional support.
In Q4 2025, Zoetis reported strong financials with a 3.02% YoY revenue increase to $2.387 billion, a 3.79% YoY net income increase to $603 million, and a 6.98% YoY EPS increase to $1.38. Gross margin improved to 68.96%, up 1.38% YoY, indicating solid operational efficiency.
Analyst sentiment is mixed but leans positive. Citi initiated a Buy rating with a $145 price target, highlighting long-term growth potential. BofA raised its price target to $140 but maintained a Neutral rating. UBS lowered its price target to $136 and kept a Neutral rating. Nephron Research downgraded the stock to Hold, citing a lack of organic growth.
